Friday
Jul012016

SPARCtool updated to version 8.1 

version 8.1 release notes (June 2016)

www.sparctool.com 

SPARCtool 

  • added an estimate for “Patient’s annual risk of stroke or TIA with no therapy if they did NOT have AF (for comparison):” based on Mitchell LB, Southern DA, Galbraith D, et al. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores. Heart. 2014;100(19):1524–1530. doi:10.1136/heartjnl–2013–305303. CHA2DS2-VASc preducts stroke in non-AF patients simiarly well to AF patients. The risk estimates are much lower for non-AF patients, of course. This is added to SPARCtool based on feedback that it is valuable for patients to see how much higher their stroke risk is because of AF vs. without it.
  • made the bleeding bars in the graph less alarmingly red
  • made the legend title for bleeding in the graph shorter
  • added a “Which therapy options to HIDE?” function. You can use this to tailor discussions with patients to the options you consider viable for whatever reason. It applies to the table and the detailed risk estimates. It does NOT affect the bars shown in the graph [I will fix this in the future].
  • added individual stroke and bleeding risk graphs * added ability to hide either or both graphs * moved the renal function warnings into the drug name bars to save space

 

version 8 release notes (June 2016)

SPARCtool

  • removed CHADS2 entirely. Although CHADS2 and CHA2DS2-VASc perform similarly as prediction tools (Olesen JB, et al. BMJ 2011;342:d124–4), it is no more difficult to use the CHA2DS2-VASc criteria and using one or the other simplifies the layout without losing any predictive performance.
  • added a new “Hypertension (SBP>160 mmHg) for HAS-BLED” since the HTN criteria for CHA2DS2-VASc and HAS-BLED are different.
  • fixed the units on SCr to “mcmol/L”
  • removed color fills for a cleaner look
  • fixed the “Age” logic. Now it’s a 3-position radio-button.
  • improved the layout of the “1 in X” statements throughout
  • added a “Reset” button to clear all the settings
  • removed “population average” values from bleeding table and graph wherever a HAS-BLED estimate exists
  • reformatted all the input areas
  • explicit definition of major bleeding
  • warnings for HAS-BLED >6 of no reliable risk data and explicit “>X%” notation for HAS-BLED bleed risks when score is >6.

SPARCmobile

  • corresponding changes as made to SPARCtool above
Sunday
Oct272013

Know Your Birth Control Rights

Updated! 

Friday
Mar082013

SPARCtool Updated

version 6.21 release notes

SPARCmobile

  • updated the disclaimer
  • fixed truncated renal dysfunction warning for new OACs on iPhone and increased visibility of warnings.
  • changed text of the warnings to “RENAL FUNCTION WARNING: Consult product monograph.” - dosage adjustment thresholds and stragtegies are evolving, so no specific advice is offered in the SPARCtool.
  • lightened most of the fill colors
  • updated dabigatran 150mg thromboembolism risk with updated RE-LY data (updated RR 0.66 −-> 0.65, RRR vs. warfarin from 78% to 79%) [Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly Identified Events in the RE-LY Trial. N Engl J Med 2010;363:1875–6.]
  • corrected major bleeding risk of ASA+clopidogrel to be the same as warfarin based on ACTIVE-W.
  • added tabular view of the risks

SPARCtool

  • updated the disclaimer
  • changed text of the warnings to "WARNING: may be contraindicated or require dosage reduction depending on degree of renal dysfunction. Consult your country's monograph."
  • dosage adjustment thresholds and stragtegies are evolving, so no specific advice is offered in the SPARCtool.
  • lightened most of the fill colors
  • updated dabigatran 150mg thromboembolism risk with updated RE-LY data (updated RR 0.66 −-> 0.65, RRR vs. warfarin from 78% to 79%) [Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly Identified Events in the RE-LY Trial. N Engl J Med 2010;363:1875–6.]
  • corrected major bleeding risk of ASA+clopidogrel to be the same as warfarin based on ACTIVE-W.
  • added tabular view of the risks
  • added graphical representation of the risks (requires Adobe Flash to view)
Thursday
Nov292012

SPARCtool Updated to version 6.1

Release Notes

version 6.1 release notes

  • edited mobile/standard links to map to new site www.sparctool.com
  • edited sparcnotes links to map to new site and completely rewrote and reorganized SPARCtool Notes
  • fixed date field width on regular version
  • updated CHADS2 and CHA2DS2-VASc risk estimates to use BMJ 2011;342:d124, 10 year followup estimates.
  • upated all the CHADS2 risk descriptors to match the CHADS-VASc one based on BMJ 2011;342:d124, which is paraphrased as "ischemic stroke+thromboembolism"
  • updated warfarin population average major bleeding risk from 2.6 to 3.8%/year based on CMAJ November 26, 2012 cmaj.121218
  • add a reference for bleeding risk CPR vs. clinician judgement
  • added a warning for dabigatran, rivaroxaban, apixaban if "abnormal renal function" is checked in HAS-BLED
  • added a disclaimer to top of both tools
Monday
Oct292012

The Star Wars That I Used to Know